JPRN-UMIN000027522已完成2 期
A study of gemtuzumab ozogamicin in combination with G-CSF after CAG or MEC (CA-G-GO therapy or MEC-G-GO therapy) for relapsed or refractory acute myeloid leukemia. - Phase II study of CA-G-GO or MEC-G-GO therapy for relapsed or refractory acute myeloid leukemia.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 76years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Pregnant and/or lactating woman 2. History of hematopoietic stem cell transplantation 3. History of interstitial pneumonitis or ARDS 4. History of administration of GO 5. Uncontrolled infection 6. History of veno-occlusive disease 7. History of cardiac dysfunction induced by GO 8. Positive for HBV, HCV and HIV 9. MDS or AML derived from MDS 10. If physicians disagree to attend this study
研究者
相似试验
进行中（未招募）
1 期
Phase II Study on Gemtuzumab Ozogamicin in Combination with All-trans-Retinoic Acid, high-dose Cytarabine and Mitoxantrone in Patients with primary refractory acute myeloid leukemia [GO-A-HAM] - GO-A-HAMEUCTR2004-003739-30-ATniversitätsklinikum Ulm / University Clinical Center Ulm84
进行中（未招募）
不适用
Gemtuzumab ozogamicin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61-75 years old with previously untreated AML: a randomized phase III trial (AML- 17) of the EORTC-LG and the GIMEMA-ALWP.EUCTR2005-001347-37-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
已完成
不适用
Phase I study of Gemtuzumab Ozogamicin given in combination with Enocitabine and Daunorubicin as induction therapy for elderly patients with acute myeloid leukemiaacute myeloid leukemiaJPRN-UMIN000002603Japan Adult Leukemia Study Group18
招募中
2 期
Study of the efficacy and safety of gemtuzumab ozogamicin treatment intervention with measurable residual disease as an index for AYA/adult acute myeloid leukemia with t(8;21) and inv(16)JPRN-jRCTs041200063Toshihiro Miyamoto117
进行中（未招募）
1 期
Gemtuzumab Ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy: a randomized phase II/III trial (AML-19)of the EORTC-LG and GIMEMA-ALWPElderly patients (61-75 years not eligible for intensive chemotherapyage > 75 years), with previously untreated, primary or secondary (no after other myeloproliferative diseases) AML (except M3).MedDRA version: 14.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-004356-39-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER259